World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 80 17032 16014 233 230 804 25424

Josep-Maria Ribera publications per year

The chart shows the history of publications by Josep-Maria Ribera between 1982 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Josep-Maria Ribera published across 44 years, from 1982 to 2025, averaging 21.7 papers a year. Output peaked at 79 publications in 2023. 62 of the 955 publications appeared in the last two years.

No. of publications
25 50 75
Bar chart. Horizontal axis: year, 1982 to 2025. Vertical axis: number of publications, 0 to 79. Peak 79 publications in 2023. 1982: 2 publications 1983: 7 publications 1984: 7 publications 1985: 6 publications 1986: 3 publications 1987: 9 publications 1988: 6 publications 1989: 11 publications 1990: 9 publications 1991: 16 publications 1992: 8 publications 1993: 9 publications 1994: 5 publications 1995: 9 publications 1996: 10 publications 1997: 17 publications 1998: 12 publications 1999: 14 publications 2000: 14 publications 2001: 9 publications 2002: 19 publications 2003: 10 publications 2004: 26 publications 2005: 25 publications 2006: 28 publications 2007: 38 publications 2008: 29 publications 2009: 23 publications 2010: 30 publications 2011: 36 publications 2012: 36 publications 2013: 28 publications 2014: 33 publications 2015: 42 publications 2016: 29 publications 2017: 38 publications 2018: 21 publications 2019: 34 publications 2020: 35 publications 2021: 36 publications 2022: 35 publications 2023: 79 publications 2024: 31 publications 2025: 31 publications
1982 2025

955 publications in total across all disciplines

View publications per year as a table
Josep-Maria Ribera: publications per year, 1982 to 2025
Year Publications
1982 2
1983 7
1984 7
1985 6
1986 3
1987 9
1988 6
1989 11
1990 9
1991 16
1992 8
1993 9
1994 5
1995 9
1996 10
1997 17
1998 12
1999 14
2000 14
2001 9
2002 19
2003 10
2004 26
2005 25
2006 28
2007 38
2008 29
2009 23
2010 30
2011 36
2012 36
2013 28
2014 33
2015 42
2016 29
2017 38
2018 21
2019 34
2020 35
2021 36
2022 35
2023 79
2024 31
2025 31
Total 955
Download as CSV

Josep-Maria Ribera publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Josep-Maria Ribera sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 801–820 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 804 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204 804
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Josep-Maria Ribera D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Josep-Maria Ribera sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 80–81 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972 80
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Josep-Maria Ribera is affiliated with the Autonomous University of Barcelona in Spain and specializes primarily in the field of Medicine, with extensive research contributions in Hematology.

Their research spans several subfields including:

  • Hematology
  • Public Health, Environmental and Occupational Health
  • Oncology
  • Genetics
  • Pathology and Forensic Medicine

Major research topics covered by their work include:

  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • CAR-T cell therapy research
  • Childhood Cancer Survivors' Quality of Life

Josep-Maria Ribera has authored multiple papers. Selected recent publications include:

  • Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia, 2020, Blood
  • Management of ALL in adults: 2024 ELN recommendations from a European expert panel, 2024, Blood
  • Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, 2024, JAMA
  • Risk factors and outcome of COVID-19 in patients with hematological malignancies, 2020, Experimental Hematology and Oncology
  • Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group, 2021, Leukemia

The venues most frequently publishing Josep-Maria Ribera's work include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Medicina Clínica (English Edition)
  • Medicina Clínica
  • HemaSphere

Their frequent co-authors are:

  • Mireia Morgades
  • Pau Montesinos
  • Anna Torrent
  • Jordi Ribera
  • Eulàlia Genescà

Best Publications

  • Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

    Hagop M Kantarjian;Anthony Stein;Nicola Gökbuget;Adele K. Fielding

  • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

    Max S. Topp;Nicola Gökbuget;Anthony S. Stein;Gerhard Zugmaier

  • Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  • Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

    Bosch F;López-Guillermo A;Campo E;Ribera Jm

  • Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

    M. Bruggemann;A. Schrauder;T. Raff;H. Pfeifer

  • High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

    Joan Bladé;Laura Rosiñol;Ana Sureda;Josep M. Ribera

  • Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

    Miguel A. Sanz;Pau Montesinos;Chelo Rayón;Alexandra Holowiecka

  • Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

    A. López-Guillermo;J. Cid;A. Salar;A. López

  • Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

    Juan José Lahuerta;Maria Victoria Mateos;Joaquin Martínez-López;Laura Rosiñol

  • Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    D. Hoelzer;R. Bassan;H. Dombret;A. Fielding

  • Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

    Josep-María Ribera;Albert Oriol;Miguel-Angel Sanz;Mar Tormo

  • Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

    Marta Pratcorona;Salut Brunet;Josep Nomdedéu;Josep Maria Ribera

  • Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

    Albert Oriol;Susana Vives;Jesús-María Hernández-Rivas;Mar Tormo

  • Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

    Josep-Maria Ribera;Albert Oriol;Mireia Morgades;Pau Montesinos

  • Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival

    David Valcárcel;Rodrigo Martino;Dolores Caballero;Jesus Martin

  • Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes

    Francesc Solé;Elisa Luño;Carmen Sanzo;Blanca Espinet

  • Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

    Philippe Rousselot;Marie Magdelaine Coudé;Nicola Gokbuget;Carlo Gambacorti Passerini

  • Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial.

    E Cobo;J Cortés;J M Ribera;F Cardellach

  • Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/ Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

    Anna Sureda;Carme Canals;Reyes Arranz;Dolores Caballero

  • Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

Frequent Co-Authors

Albert Oriol
Albert Oriol Autonomous University of Barcelona
Alberto Orfao
Alberto Orfao University of Salamanca
Jorge Sierra
Jorge Sierra Autonomous University of Barcelona
Anna Sureda
Anna Sureda Autonomous University of Barcelona
Dieter Hoelzer
Dieter Hoelzer Goethe University Frankfurt
Armando López-Guillermo
Armando López-Guillermo University of Barcelona
Francesc Solé
Francesc Solé Autonomous University of Barcelona
Rodrigo Martino
Rodrigo Martino Hospital de Sant Pau
Emili Montserrat
Emili Montserrat University of Barcelona
Neus Villamor
Neus Villamor University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide range of online degrees and career pathways in healthcare. Many students seek flexible, affordable options to expand their qualifications or start new careers in the fast-growing medical field.

A medical coding certification online is a great entry point, offering essential skills for working with patient records, insurance, and healthcare administration. For those interested in direct patient care, there are affordable online nursing programs that prepare you for a rewarding career as a registered nurse.

If you already have nursing experience and want to advance further, look into the most affordable online nurse practitioner programs to become a primary or specialized care provider. For the highest level of clinical expertise, consider the cheapest dnp programs online. These doctoral programs can position you for leadership, research, or advanced practice roles.

Choosing an online degree offers flexibility and affordability, making it easier than ever to launch or advance your healthcare career.

Best Scientists Citing Josep-Maria Ribera

Trending Scientists

Recently Published Articles